ABSTRACT
Resumo Estudo prospectivo e transversal, para determinar a prevalência de prejuízo cognitivo decorrente da quimioterapia e explorar fatores preditores e mediadores em sobreviventes de câncer de mama. Utilizou-se o Termômetro de Distress, Escala de Ansiedade e Depressão, Functional Assessment of Chronic Illness Therapy-General e Cognitive Function. As sobreviventes (N = 62) reportaram uma alta prevalência de distress (46,8%) e de ansiedade (24,2%), com baixos escores nas subescalas déficit cognitivo e habilidades cognitivas percebidos. O funcionamento cognitivo esteve associado à idade (β = 1,42; p = 0,002), atuação profissional (β = -23,12; p = 0,004), depressão (β = -5,43; p = 0,001) e qualidade de vida (β = 1,24; p = 0,001). Prejuízo cognitivo deve ser considerado no serviço de Psico-Oncologia.
Abstract Prospective and cross-sectional study to determine the prevalence of cognitive impairment resulting from chemotherapy, and to explore predictors and mediators in survivors of breast cancer. We used the Distress Thermometer, Hospital Anxiety and Depression Scale, Functional Assessment of Chronic Illness Therapy-General and Functional Assessment of Cancer Therapy-Cognitive Function. Survivors (N = 62) reported a high prevalence of distress (46.8%) and anxiety (24.2%), with low scores on cognitive deficit and cognitive skills perceived subscales. Cognitive functioning was associated with age (β = 1.42; p = 0.002), professional performance (β = -23.12; p = 0.004), depression (β = -5.43; p = 0.001), and quality of life (β = 1.24; p = 0.001). Cognitive impairment must be considered in Psycho-Oncology service.